Financing channel feed – Endpoints News

Financing channel feed

Mega-money biotech round spills $116M into gene therapy upstart Freeline

7 years ago

Determined to build the leading biotech player in a new R&D space, Steven Holtzman lines up $55M for the next stage at Decibel

7 years ago

Replacing lab rats? Bay Area tech fund backs Emulate's $36M round to commercialize 'organ chip' tech

7 years ago

High-profile Chinese investor Vincent Cheung plays a lead role in raising $100M round for a Boston start-up

7 years ago

Johns Hopkins spinout WindMIL grabs $32.5M to fuel its work on a next-gen approach to cell therapy

7 years ago

Verrica Pharma bankrolls PhIII with a $75M IPO raise for lead skin drug

7 years ago

UK bank launches £2.5B plan to fund innovation, with a special place for its long-ailing biotech scene

7 years ago

SF venture fund Alta Partners misses original mark, raising $130M for ninth fund

7 years ago

Act One: Anti-aging team at Juvenescence adds $50M to the cache as it builds steam on development efforts

7 years ago

AI team at Insilico gets some major league backing from China as Alex Zhavoronkov builds global network

7 years ago

After cash funneling scandal, biotech billionaire Soon-Shiong charges on with Nant IPO

7 years ago

Ex-con Sam Waksal's startup prices IPO, joining parade of biotechs with Nasdaq news

7 years ago

Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie

7 years ago

Tilting at vaccines giants, SutroVax fuels up on a $170M-plus quest to vault past the world's best-selling vaccine

7 years ago

Manufacturing experts at Hangzhou Just Biotherapeutics bank $35M for stealthy R&D in China and the US

7 years ago

Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX's door with an IPO application

7 years ago

Rich Heyman's Metacrine tacks on another $65M to tackle a superior NASH drug

7 years ago

Pfizer adds $600M to its venture group, with a special focus on the neurosciences field it just retreated from

7 years ago

Clinical trial disruptor Science 37 in talks with SoftBank on a $150M investment — Recode

7 years ago

Hours after filing $150M IPO, Tricida shares positive PhIII trial results on CKD drug

7 years ago

With $1.2B NASH deal behind them, Nimbus raises $65M for I/O, other R&D

7 years ago

Stanford spinout Forty Seven arrives at ASCO with a snapshot of promising CD47 data — and a $115M IPO in hand

7 years ago

Neoantigen pioneer Neon Therapeutics casts off in search of $115M IPO to fuel the race to a personalized cancer treatment

7 years ago

Bay Area startup Cortexyme gains a $76M round to back a PhII Alzheimer's study, with a new target in their sights

7 years ago

First page Previous page 126 127 128129130 131 132 Next page Last page